PT  - JOURNAL ARTICLE
AU  - Walker, Gregory J.
AU  - Clifford, Vanessa
AU  - Bansal, Nidhi
AU  - Stella, Alberto Ospina
AU  - Turville, Stuart
AU  - Stelzer-Braid, Sacha
AU  - Klein, Laura D
AU  - Rawlinson, William
TI  - SARS-CoV-2 in human milk is inactivated by Holder pasteurization but not cold storage
AID  - 10.1101/2020.06.18.20134395
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.18.20134395
4099  - http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134395.short
4100  - http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134395.full
AB  - As the COVID-19 pandemic evolves, human milk banks worldwide continue to provide donor human milk to vulnerable infants who lack access to mother’s own milk. Under these circumstances, ensuring the safety of donor human milk is paramount, as the risk of vertical transmission of SARS-CoV-2 is not well understood. Here, we investigate the inactivation of SARS-CoV-2 in human milk by pasteurisation, and the stability of SARS-CoV-2 in human milk under cold storage (freezing or refrigeration). Following heating to 63°C or 56°C for 30 minutes, SARS-CoV-2 replication competent (i.e. live) virus was undetected in both human milk and the control medium. Cold storage of SARS-CoV-2 in human milk (either at 4°C or - 30°C) did not significantly impact infectious viral load over a 48 hour period. Our findings demonstrate that SARS-CoV-2 can be effectively inactivated by Holder pasteurisation, and confirm that existing milk bank processes will effectively mitigate the risk of transmission of SARS-COV-2 to vulnerable infants through pasteurised donor human milk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was secured for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Australian Red Cross Lifeblood Human Research Ethics Committee (Clifford 27042020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author (WR), upon reasonable request.SARS-CoV-2severe acute respiratory syndrome coronavirus 2COVID-19coronavirus disease 2019MEMminimum essential mediumTCID5050% tissue culture infectious dose